Maze Therapeutics
Watchlist
Maze Therapeutics (MAZE): Analysts Focus After IPO - Experts See Up to 175% Price Potential!
Reading Time: 4 minutes
Maze Therapeutics Inc. (MAZE) specializes in precision medicines for genetic diseases. Among its leading programs are MZE829 and MZE782, which represent novel approaches to treating chronic kidney diseases. MZE829 aims to inhibit the APOL1 protein, which is associated with certain kidney diseases. People with specific variants of the APOL1 gene have an increased risk of kidney diseases. MZE829 is currently in Phase 2 clinical trials. MZE782, on the other hand, is a compound that targets the SLC6A19 protein. This candidate could potentially help...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
